Global landscape for pulmonary fibrosis treatment: a data-driven perspective from clinical trials
Chunyan Zhao, Chang Song, Yue Zhou, Jing Luo, Shaochu Zheng, Xiaojuan Li, Yuhai Dang, Nuo Yang, Jinliang Kong · 2026
Read Global landscape for pulmonary fibrosis treatment: a data-driven perspective from clinical trials by Chunyan Zhao, Chang Song, Yue Zhou, Jing Luo, Shaochu Zheng, Xiaojuan Li, Yuhai Dang, Nuo Yang, Jinliang Kong (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13523513.txt.
Description
Chunyan Zhao and colleagues map, in a 2026 data-driven review, the worldwide landscape of clinical trials for pulmonary fibrosis treatment. Pulmonary fibrosis covers chronic lung diseases where scarring impairs breathing and can end in respiratory failure. Knowing where trials cluster, and what they test, guides future strategy.
Searching a pharma intelligence database produced 1,203 interventional trials. Activity grew in three stages, with a surge in 2020, and concentrated in the United States with 316 trials and China with 285, while only 128 were multinational. Two established drugs still dominated, nintedanib in 94 trials and pirfenidone in 88. Endpoints focused on safety and on forced vital capacity, a breathing measure. The disease range widened beyond idiopathic disease, and the authors call for more collaboration and precision grouping.
Catalog record
| CREATOR | Chunyan Zhao, Chang Song, Yue Zhou, Jing Luo, Shaochu Zheng, Xiaojuan Li, Yuhai Dang, Nuo Yang, Jinliang Kong |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 40771 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |